Cargando…
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double‐blind, pilot study
The primary treatment outcomes of a phase 2, randomized, double‐blind, pilot study evaluating safety, physiological, and pharmacological effects of elosulfase alfa in patients with Morquio A syndrome are herewith presented. Patients aged ≥7 years and able to walk ≥200 m in the 6‐min walk test (6MWT)...
Autores principales: | Burton, Barbara K., Berger, Kenneth I., Lewis, Gregory D., Tarnopolsky, Mark, Treadwell, Marsha, Mitchell, John J., Muschol, Nicole, Jones, Simon A., Sutton, V. Reid, Pastores, Gregory M., Lau, Heather, Sparkes, Rebecca, Genter, Fred, Shaywitz, Adam J., Harmatz, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744659/ https://www.ncbi.nlm.nih.gov/pubmed/26069231 http://dx.doi.org/10.1002/ajmg.a.37172 |
Ejemplares similares
-
Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open‐label, phase 2 study
por: Harmatz, Paul R., et al.
Publicado: (2016) -
Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y
por: Jones, Simon A., et al.
Publicado: (2015) -
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
por: Hendriksz, Christian J., et al.
Publicado: (2016) -
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
por: Qi, Yulan, et al.
Publicado: (2014) -
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome
por: Lee, Chung-Lin, et al.
Publicado: (2022)